Capricor Therapeutics, Inc.
CAPR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.58 | -0.02 | 0.29 | -1.17 |
| FCF Yield | -4.75% | -1.75% | -3.20% | -2.32% |
| EV / EBITDA | -16.65 | -16.50 | -65.04 | -34.51 |
| Quality | ||||
| ROIC | -26.14% | -18.89% | -5.09% | -17.56% |
| Gross Margin | 0.00% | 0.00% | 96.62% | 84.00% |
| Cash Conversion Ratio | – | 0.78 | 0.26 | 2.08 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.47% | 12.30% | 46.36% | 105.90% |
| Free Cash Flow Growth | -184.82% | 51.23% | -32.73% | 5.40% |
| Safety | ||||
| Net Debt / EBITDA | 0.86 | 1.12 | 1.34 | 5.28 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -890.67 | -1,166.18 | -1,876.01 | -1,608.77 |